地衣芽孢杆菌活菌胶囊治疗非酒精性脂肪性肝病的疗效评价

魏敏; 夏露; 平晶; 程文芳

doi:10.3969/j.issn.1671-038X.2018.01.10

地衣芽孢杆菌活菌胶囊治疗非酒精性脂肪性肝病的疗效评价

- 1 南京医科大学附属江宁医院消化科, 江苏南京 210000;
- 2 江苏省人民医院消化科, 江苏南京 210000

详细信息

作者简介:
魏敏,女,主治医师,主要从事肝胆胰脾临床疾病的诊治及消化道早期肿瘤的内镜下诊治研究

通讯作者: 程文芳,E-mail:chengwenfang@aliyun.com

中图分类号: R575.5

收稿日期: 2017-07-15

Effects of Bacillus Licheniformis capsule on non-alcoholic fatty liver disease

- 1 Department of Gastroenterology, Jiangning Hospital Affiliated to Nanjing Medical University, Nanjing 210000, China;
- 2 Department of Gastroenterology, Jiangsu Province People's Hospital, Nanjing 210000, China

More Information

Corresponding author: CHENG Wen-fang, E-mail: chengwenfang@aliyun.com

Received Date: 15 July 2017

摘要

摘要: [目的]评价地衣芽孢杆菌活菌胶囊治疗非酒精性脂肪性肝病 (NAFLD) 的临床疗效。[方法]82例NAFLD患者被随机将患者分为治疗组 (41例) 与对照组 (41例)。2组均避免不健康的饮食, 保持健康的生活方式。对照组患者予甘草酸二铵肠溶胶囊治疗, 治疗组患者在对照组基础上予以地衣芽孢杆菌活菌胶囊治疗, 2组患者均连续治疗12周。治疗前及治疗12周后所有患者进行肝脏B超检查, 比较2组患者临床症状改善情况, 生化指标 (ALT、AST, TG、TC) 情况以及整体临床疗效。[结果]治疗组患者腹胀改善情况优于对照组 (P＜0.05);治疗后2组患者肝功能指标 (ALT、AST) 血脂 (TG、TC) 指标均有下降, 治疗组ALT、AST、TG、TC水平低于对照组 (P＜0.05)。治疗组总有效率高于对照组 (P＜0.05)。[结论]甘草酸二铵肠溶胶囊联合地衣芽孢杆菌活菌胶囊治疗NAFLD的临床疗效确切, 可有效改善患者症状、血脂及肝功能, 疗效优于单用甘草酸二铵肠溶胶囊。
- 非酒精性脂肪性肝病 /
- 地衣芽孢杆菌活菌胶囊 /
- 治疗
Abstract: [Objective] To evaluate the efficacy of Bacillus Licheniformis Capsule.Live in treatment of NAFLD.[Methods] Eighty-two NAFLD patiemts were randomized into treatment group (41 cases) and control group (41 cases).Help people in both groups to avoid unhealthy diets, maintain healthy lifestyles.Patients in control group were treated with Diammonium glycrrhizinate enteric-coated capsules, and the treatment group was additionally give Bacillus Licheniformis Capsule.Live.The course of treatment was 12 weeks.Clinical manifestation, hepatic functiona (ALT and AST) and blood lipids (TG and TC) were observed during the therapeutic course of 12 weeks and their clinical efficacy had been evaluated.[Results] The patients' symptoms were improved significantly after treatment, the treatment group patients with abdominal distension improvement is better than that of control group (P＜0.05);there was significant difference (P＜0.05).Hepatic functiona (ALT、AST) and blood lipids (TG、TC) were obviously improved after treatment, there was significant difference (P＜0.05) between two groups.The total effective rate of treatment group was 92.5%and that of control group was 75.6%, the difference between these two groups was significant (P＜0.05).[Conclusion] Diammonium glycrrhizinate enteric-coated capsules combined with Bacillus Licheniformis Capsule.Live can be used as an ideal treatment for non-alcoholic fatty liver disease.
- NAFLD /
- bacillus licheniformis capsule /
- treatment

HTML全文

参考文献(18)

[1]	中华医学会肝病学分会脂肪肝和酒精性肝病学组.非酒精性脂肪性肝病诊疗指南 (2010年修订版)[J].中华肝脏病杂志, 2010, 18 (3):163-166.
[2]	Wang FS, Fan JG, Zhang Z, et al.The global burden of liver disease:the major impact of China[J].Hepatology, 2014, 60 (6):2099-2108.
[3]	Bellentani S, Scaglioni F, Marino M, et al.Epidemiology of non-alcoholic fatty liver disease[J].Dig Dis, 2010, 28 (1):155-161.
[4]	Caballería L, Ma AA, Torán P, et al.Prevalence and factors associated with the presence of non-alcoholic fatty liver disease in an apparently healthy adult population in primary care units[J].BMC Gastroenterol, 2007, 7 (1):1-6.
[5]	Lonardo A, Ballestri S, Marchesini G, et al.Nonalcoholic fatty liver disease:aprecursor of the metabolic syndrome[J].Dig Liver Dis, 2015, 47 (3):181-190.
[6]	Compare D, Coccoli P, Rocco A, et al.Gut-Liverax:the impact of gutmicrobiata on non alcoholic fatty liver disease[J].Nutr Metab cardiovasc Dis, 2012, 22 (6):471-476.
[7]	Harris K, Kassis A, Major G, et al.Is the gut microbiota a new factor contributing to obesity and its metabolic disorders?[J].J Obes, 2012, 2012:879151.
[8]	Shen J, Obin MS, Zhao L.The gut microbiota, obesity and insulin resistance[J].Mol Aspects Med, 2013, 34 (1):39-58.
[9]	Bai AP, Ouyang Q, Zhang W, et al.Probiotics inhibit TNFalpha-induced interleukin-8 secretion of HT29 cells[J].World J Gastroenterol, 2004, 10:455-457.
[10]	Araya M, Morelli L, Reid G, et al.Joint FAO/WHO Working Group Report on Guidelines for the Evaluation of Probiotics in Food London[J].Ontario, Canada, 2002.
[11]	Ma Y, Li L, Yu CH, et al.Effects of probiotics on nonalcoholic fatty liver disease:a meta-analysis[J].World J Gastroenterol, 2013, 19 (40):6911-6918.
[12]	Miele L, Valenza V, La Torre G, et al.Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease[J].Hepatology, 2009, 49 (6):1877-1887.
[13]	Arslan N.Obesity, fatty liver disease and intestinal microbiota[J].World J Gastroenteml, 2014, 20 (44):16452-16463.
[14]	Ley RE, Bäckhed F, Turnbaugh P, et al.Obesity alters gut microbial ecology[J].Proc Natl Acad Sci USA, 2005, 102 (31):11070-11075.
[15]	Ridaura VK, Faith JJ, Rey FE, et al.Gut microbiota from twins discordant for obesity modulate metabolism in mice[J].Science, 2013, 341 (6150):124-214.
[16]	Turnbaugh PJ, Ley RE, Mahowald MA, et al.An obesity-associated gut microbiome with increased capacity for energy harvest[J].Nature, 2006, 444 (7122):1027-1031.
[17]	Kim H, Kim DH, Seo KH, et al.Modulation of the intestinal microbiota is associated with lower plasma cholesterol and weight gain in hamsters fed chardonnay grape seed flour[J].J Agric Food chem, 2015, 63 (5):1460-1467.
[18]	de Moreno de LeBlanc A, LeBlanc JG.Effect of probiotic administration on the intestinal microbiota, current knowledge and potential applications[J].World J Gastroenterol, 2014, 20 (44):16518-16528.